medigraphic.com
ISSN 0188-9796 (Print)

2003, Number 1

<< Back Next >>

Rev Endocrinol Nutr 2003; 11 (1)

Insulin levels and cardiovascular risk factors in hypertensive versus normotensive mexican people

Vázquez CC, Salinas OS, Gómez DRA, Rosso JMM, Jimenéz VM, Argüero SR

Language: Spanish
References: 32
Page: 7-14
PDF size: 97.60 Kb.


ABSTRACT

Background: To analyze the presence of hyperinsulinaemia and other cardiovascular risk factors in a group of Mexican hypertensive subjects and to compare them with a normotensive control group. Research design and methods: All subjects in the study underwent a clinical evaluation and a 75 g oral glucose tolerance test (OGTT) with measurements of glucose, insulin and C peptide at 0, 60, and 120 minutes. At basal time total cholesterol (TC), tryglicerides (TG), high (HDL) and low (LDL) density lipoproteins cholesterol, fibrinogen and uric acid were also quantified. Patients taking thiazides, beta-blocker drugs or with renal or liver disease, impaired glucose tolerance or diabetes mellitus were not included. Statistical analysis: Univariated analysis included mean values and standard deviations. Comparative tests were made with Students t test, Mann-Whitney U test and variance analysis (ANOVA) adjusted by sex, age and body mass index (BMI). A correlation of insulin with other variables was studied with Pearson and Spearman tests. Homeostatic model analysis (HOMA) was used for the evaluation of insulin resistance in both groups, their differences were also analyzed. HOMA was also utilized for compared normo and hypertensive subjects with a BMI above 27 kg/m2 or below 25 kg/m2. Results: Hypertensive subjects (n = 332) showed higher insulin levels than normotensive subjects (n = 485), at all times during the OGTT, 0 min 21.15 ± 1.43 vs 17.5 ± 0.70 uU/mL (p ‹ 0.001), 60 min 108.0 ± 5.88 vs 88.0 ± 4.09 uU/mL (p › 0.001) and 120 min 82.8 ± 5.41 vs 74.3 ± 3.75 uU/mL (p ‹ 0.01). ANOVA adjusted by sex, age and BMI keep that significance at 120 min (p 0.007). C-peptide showed a significative difference at 120 min (p 0.005). There was a positive correlation between fasting insulin in both groups with weight, BMI, waist to hip ratio, blood pressure, triglycerides, C-peptide and a negative one with HDL-C and the glucose/insulin ratio in the hypertensive group. HOMA showed higher degrees of insulin resistance in the hypertensive group when compared with normotensive subjects 6.08 ± 6.41 vs 4.52 ± 3.47 (p ‹ 0.0001); when only those with a BMI above 27 kg/m2 were compared the difference persisted 7.11 ± 7.4 vs 5.77 ± 4.02 (p ‹ 0.02), however no difference was found in those with a BMI less than 25 kg/m2. Conclusions: Hyperinsulinemia and insulin resistance were found in a Mexican hypertensive group when compared with normotensive subjects, this difference persisted even when sex, age an BMI were adjusted for the analysis.


REFERENCES

  1. Ferrannini E, Buzzigoli G, Bonadonna R, Giorico MA, Oleggini M, Graziadel L, Pedrinelli R, Brandi L, Bevilacqua S. Insulin resistance in essential hypertension. N Engl J Med 1987; 317: 350-357.

  2. DeFronzo RA. Lily Lecture. The triumvirate: B-cell, muscle, liver, A collusion responsible for NIDDM. Diabetes 1988; 37: 667-687.

  3. Cooney GJ, Storlien LH. Insulin action, thermogenesis and obesity. Bailliere’s Clinic Endocr Metab 1994; 8(3): 481-507.

  4. Caro JF. Clin Rev 26 Insulin resistance in obese and non obese man. J Clin Endoc Metab 1991; 73: 691-695.

  5. DeFronzo RA, Ferranninni E. Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991; 14: 173-194.

  6. Fontbonne A, Charles MA, Thibult N, Richard JL, Claude JR, Warnet JM, Rosselin GE, Eschwege E. Hyperinsulinemias predictor of coronary heart disease mortality in a healthy population: The Paris Prospective Study, 15 year follow-up. Diabetologia 1991; 34: 356-361.

  7. Pyörälä M, Miettinen H, Laakso M, Pyörälä K. Plasma insulin and all causes, cardiovascular and noncardiovascular mortality. The 27 years follow-up. Results of the Helsinki Policem Study. Diabetes Care. 2000; 23: 1097-1102.

  8. Taylor R. Insulin action 1991. Clin Endocrinol 1991; 34: 159-171.

  9. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.

  10. Despres JP. Dyslipidaemia and obesity. Bailliere’s Clinic Endocr Metab 1994; 8(3): 629-660.

  11. DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 1992; 15: 218-268.

  12. Juhan-Vague Y, Alessi MC, Vague P. Increased plasma plasminogen activator inhibitor-l levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 1991; 34: 457-62.

  13. Emst E. Fibrinogen as a cardiovascular risk factor meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-963.

  14. King GL, Wakasaki H. Theorical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular disease in diabetes. Diabetes Care 1999; 22(Suppl. 3): C31-7.

  15. Clausen T. Regulation of active Na-K transport in skeletal muscle. Physiol Rev 1986; 66: 542.

  16. Landin K, Indgard F, Saltin B, Lingarde F, Satin B, Smith U. The skeletal muscle Na/K ratio is not increased in hypertension 1991; 9(1): 65-69.

  17. Arye Leu-Ran. Thrifty genotype: How applicable is it too obesity and type 2 diabetes? Diabetes Reviews 1999; 7: 1-22.

  18. Anderson EA, Mark AL. The vasodilator action of insulin implication for the insulin hypotesis of hypertension. Hypertension 1993; 21: 136-411.

  19. Sawicki PT, Heinemann L, Starke A, Berger M. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia 1992; 35: 649-652.

  20. Zimmet PZ, Haffner SM, Stern MP. Essential Hypertension; An insulin resistant state. J Cardiovasc Pharmacol 1990; 15(Suppl. 5): 51.

  21. Zimmet PZ. Hyperinsulinemia how innocent a bystander? Diabetes Care 1993; 16: 56-70.

  22. Zimmet P, Dowse G, Serjeantson S, King H. The epidemiology and natural history of NIDDM lesson from the South Pacific. Diabetes Metab Rev 1990; 6: 91-124.

  23. Denker PS, Pollock VE. Fasting serum insulin levels in essential hypertension. A meta-analysis. Arch Intern Med 1992; 152: 1649-1651.

  24. Haffner SM, Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin resistance syndrome X. Diabetes 1992; 41: 715-722.

  25. Kario K, Nago N, Kayaba K, Saegusa T, Matsuo H, Goto T, Tsutsumi A, Ishikawa S, Kuroda T, Miyamoto T, Matsuo T, Shimada K. Characteristics of the insulin resistance syndrome in a Japanese population. The Jichi Medical Cohort Study. Arterioscler Thromb Vasc Biol 1996; 16: 269-274.

  26. Ohmori S, Kiyohara Y, Kato L, Ohmura T, Iwamoto H, Nacayama K, Nomiyama K, Yoshilake T, Veda K, Fujishima M. Hyperinsulinemia and blood pressure in a general Japanese population; The Hisayama Study. J Hypertens 1994; 12: 1191-1197.

  27. Woo J, Cockram CS, Lan E, Chan A, Swaminathan R. Association between insulin and blood pressure in a community population with normal glucose tolerance. J Hum Hypertens 1992; 6: 343-34.

  28. Saad MF, Lillioja S, Nyomba BL. Racial differences in the relation between blood pressure and insulin resistance. N Engl J Med 1991; 324: 733-739.

  29. Manicardi V, Camellini L, Bellodi G, Coscelli C, Ferranninni E. Evidence for on association of high blood pressure and hyperinsulinemia in obese man. J Clin Endocrinol Metab 1986; 62: 1302-1304.

  30. Multiple Risk Factor Intervention Trial Research Group: Mortality rates after 10.5 year for participants in the MRFIT: findings related to a priori hypothesis of the trial. JAMA 1990; 263: 1795-1801.

  31. Haffner S, González C, Hazuda HP, Valdez R, Mykkänen L, Stern M. Prevalence of hypertension in Mexico City and San Antonio, Texas. Circulation 1994; 90: 1542-1549.

  32. Haffner SM, Ferraninni E, Hazuda HP, Stern MP. Clostering of Cardiovascular Risk Factors in Confirmed Prehypertensive Individuals. Hypertension 1992; 20: 38-45.




2020     |     www.medigraphic.com